Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

Based on the findings of the meeting of the EWGGD on Thursday 10th September in Bad Honnef, Germany, this paper includes a position statement based on the findings of the meeting, the key recommendations for the identification and monitoring of at-risk patients threatened by the abrupt withdrawal of treatment, suggestions for the equitable distribution of the available Cerezyme, and access to other possible treatments including those that have completed phase 3 clinical trials but have not yet been licensed. Click here for the published paper.